Src-dependence and pertussis-toxin sensitivity of urokinase receptor- dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells

Blood

Volumn 94, Issue 2, 1999, Pages 649-662

  Degryse, Bernard ^b   Resnati, Massimo ^b   Rabbani, Shafaat A ^b   Villa, Antonello ^b   Fazioli, Francesca ^b   Blasi, Francesco ^a  

^a HSRaffaele   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CHYMOTRYPSIN; GUANINE NUCLEOTIDE BINDING PROTEIN; INTEGRIN; MEMBRANE RECEPTOR; PERTUSSIS TOXIN; PROTEIN TYROSINE KINASE; UROKINASE RECEPTOR; VITRONECTIN RECEPTOR;

ANIMAL CELL; ARTICLE; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; CYCLIZATION; CYTOSKELETON; MEMBRANE BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

EID: 0033566354     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.2.649.414k34_649_662     Document Type: Article

References (61)

1. Fazioli F, Blasi F: Urokinase-type plasminogen activator and its receptor: New targets for anti-metastatic therapy? Trends Pharmacol Sci 15:25, 1994
2. Blasi F: u-PA, u-PAR, PAI-1: Key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 18:415, 1997
3. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA: Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269:32380, 1994
4. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F: Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 15:1572, 1996
5. Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F: A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J 16:7279, 1997
6. Behrendt N, Ploug M, Patthy L, Houen G, Blasi F, Danø K: The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem 266:7842, 1991
7. Ploug M, Ellis V, Danø K: Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a Hydrophobic binding site exposed only on the intact receptor. Biochemistry 33:8991, 1994
8. Hoyer-Hansen G, Behrendt N, Ploug M, Danø K. Preissner KT: The intact urokinase receptor is required for efficient vitronectin binding: Receptor cleavage prevents ligand interaction. FEBS Lett 420:79, 1997
9. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA: Regulation of integrin function by the urokinase receptor. Science 273:1551, 1996
10. Cooper JA: The role of actin polymerisation in cell motility. Annu Rev Physiol 53:585, 1991
11. Ridley AJ: Membrane ruffling and signal transduction. Bioessays 16:321, 1994
12. Bretscher A: Microfilament structure and function in the cortical cytoskeleton. Annu Rev Cell Biol 7:337, 1991
13. Herman IM, Pollard TD: Relation between cell activity and the distribution of cytoplasmic actin and myosin. J Cell Biol 90:84, 1981
14. Small JV: The actin cytoskeleton. Electron Microsc Rev 1:155, 1988
15. Casscells W: Migration of smooth muscle and endothelial cells. Circulation 86:723, 1992
16. Van Leeuwen RTJ: Extracellular proteolysis and the migrating vascular smooth muscle cell. Fibrinolysis 10:59, 1996
17. Schwartz SM: Perspectives series: Cell adhesion in vascular biology. Smooth muscle migration in atherosclerosis and restenosis. J Clin Invest 99:2814, 1997
18. Okada SS, Grobmyer SR, Barnathan ES: Contrasting effects of plasminogen activators, urokinase receptor and LDL receptor-related protein on smooth muscle cell migration and invasion. Arterioscler Thromb Vasc Biol 16:1269, 1996
19. Dumler, I, Weis, A, Mayboroda, OA, Maasch, C, Jerke, U., Haller, U., Gulba, DC. The Jak/Stat pathway and urokinase receptor signalling in human aortic vascular smooth muscle cells. J Biol Chem 273:315, 1998
20. Carmeliet P, Moons L, Dewerchin M, Rosenberg S, Herbert JM, Lupu F, Collen D: Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice. J Cell Biol 140:233, 1998
21. Herbert JM, Lamarche I, Carmeliet P: Urokinase and tissue-type plasminogen activator are required for the mitogenic and chemotactic effects of bovine fibroblast growth factor and platelet-derived growth factor-BB for vascular smooth muscle cells. J Biol Chem 272:23585, 1997
22. Odekon LE, Sato Y, Rifkin DB: Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J Cell Physiol 150:258, 1992
23. Odekon LE, Blasi F, Rifkin DB: Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF-beta. J Cell Physiol 158:398, 1994
24. Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann G, Birchmeier W, Daikuhara Y, Tsubouchi H, Blasi F, Comoglio PM: Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J 11:4825, 1992
25. Naldini L, Vigna E, Bardelli A, Follenzi A, Galimi F, Comoglio PM: Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem 270:603, 1995
26. Bugge TH, Suh TT, Flick MJ, Daugherty CC, Rømer J, Solberg H, Ellis V, Danø K, Degen JL: The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J Biol Chem 270:16886, 1995
27. Dewerchin M, Van Nuffelen A, Wallays G, Bouché A, Moons L, Carmeliet P, Mulligan RC, Collen D: Generation and characterization of urokinase receptor-deficient mice, J Clin Invest 97:870, 1996
28. Rabbani SA, Rajwans N, Achbarou A, Murthy KK, Goltzman D: Isolation and characterization of multiple isoforms of the rat urokinase receptor in osteoblasts. FEBS Lett 338:69, 1994
29. Masucci MT, Pedersen N, Blasi F: A soluble, ligand binding mutant of the human urokinase plasminogen activator receptor. J Biol Chem 266:8655, 1991
30. Achbarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P, Goltzman D, Rabbani SA: Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 54:2372, 1994
31. Baggiolini M, Dewald B, Moser B: Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol 55:97, 1994
32. 2 macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem 267:14543, 1992
33. Conese M, Nykjær, Christensen EI, Petersen CM, Cremona O, Pardi R, Andreasen PA, Gliemann J, Blasi F: Alpha-2 macroglobulin receptor-dependent internalization of the urokinase receptor. J Cell Biol 131:1609, 1995
34. Bokoch GM: Chemoattractant signaling and leukocyte activation. Blood 86:1649, 1995
35. Gyetko MR, Chen GH, McDonald RA, Goodman R, Huffnagle GB, Wilkinson CC, Fuller JA, Toews GB: Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model. J Clin Invest 97:1818, 1996
36. Shapiro RL, Duquette JG, Nunes I, Roses DF, Harris MN, Wilson EL, Rifkin DB: Urokinase-type plasminogen activator-deficient mice are predisposed to staphylococcal botryomycosis, pleuritis and effacement of lymphoid follicles. Am J Pathol 150:359, 1997
37. Ossowski L, Reich E: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35:611, 1983
38. Hearing VJ, Law LW, Corti A, Appella E, Blasi F: Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 48:1270, 1988
39. Cajot JF, Schleuning WD, Medcalf RL, Bamat J, Testuz J, Liebermann L, Sordat B: Mouse Lcells expressing human prourokinase-type plasminogen activator: Effects on extracellular matrix degradation and invasion. J Cell Biol 109:915, 1989
40. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD: Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 90:5021, 1993
41. Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA, Rosenberg S: Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 56:2428, 1996
42. Hall A: Small GTP-binding proteins and the regulation of the actin cytoskeleton. Annu Rev Cell Biol 10:31, 1994
43. rho induces rapid changes in cell morphology. J Cell Biol 111:1001, 1990
44. Ridley AJ, Hall A: The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70:389, 1992
45. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A: The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 70:401, 1992
46. Burridge K, Fath K, Kelly T, Nuckolls G, Turner C: Focal adhesion: Transmembrane junctions between the extracellular matrix and the cytoskeleton. Annu Rev Cell Biol 4:487, 1988
47. Weisberg E, Sattler M, Ewaniuk DS, Salgia R: Role of focal adhesion proteins in signal transduction and oncogenesis. Crit Rev Oncog 8:343, 1997
48. David-Pfeuty T, Nouvian-Dooghe Y: Immunolocalization of the cellular src protein in interphase and NIH c-src overexpressor cells. J Cell Biol 111:3097, 1990
49. Kaplan KB, Swedlow JR, Varmus HE, Morgan DO: Association of p60c-src with endosomal membranes in mammalian fibroblasts. J Cell Biol 118:321, 1992
50. Kaplan KB, Swedlow JR, Morgan DO, Varmus HE: c-Src enhances the spreading of src-/- fibroblasts on fibronectin by a kinase-independent mechanism. Genes Dev 9:1505, 1995
51. Kaplan KB, Bibbins KB, Swedlow JR, Arnaud M, Morgan DO, Varmus HE: Association of the amino terminal half of c-Src with focal adhesions alters their properties and is regulated by phosphorylation of tyrosine 527. EMBO J 13:4745, 1994
52. Erpel T, Courtneidge SA: Src family protein tyrosine kinases and cellular signal transduction pathways. Curr Opin Cell Biol 7:176, 1995
53. Bohuslav J, Horejsi V, Hansmann C, Stockl J, Weidle UH, Majdic O, Bartke I, Knapp W, Stockinger H: Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes. J Exp Med 181:1381, 1995
54. Xue W, Mizukami I, Todd RF 3rd, Petty HR: Urokinase-type plasminogen activator receptors associate with beta 1 and beta 3 integrins of fibrosarcoma cells: Dependence on extracellular matrix components. Cancer Res 57:1682, 1997
55. Yebra M, Parry GCN, Stromblad S, Mackman N, Rosenberg S, Mueller BM, Cheresh DA: Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. J Biol Chem 271:29393, 1996
56. Clyman RI, Mauray F, Kramer RH: Beta 1 and beta 3 integrins have different roles in the adhesion and migration of vascular smooth muscle cells on extracellular matrix. Exp Cell Res 200:272, 1992
57. Koyama N, Seki J, Vergel S, Mattsson EJ, Yednock T, Kovach NL, Harlan JM, Clowes AW: Regulation and function of an activation-dependent epitope of the beta 1 integrins in vascular cells after balloon injury in baboon arteries and in vitro. Am J Pathol 148:749, 1996
58. Waltz DA, Chapman HA: Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 269:14746, 1994
59. Zhang Z, Morla AO, Vuori K, Bauer JS, Juliano RL, Ruoslahti E: The alpha v beta 1 integrin functions as a fibronectin receptor but does not support fibronectin matrix assembly and cell migration on fibronectin. J Cell Biol 122:235, 1993
60. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM, Giachelli CM: The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 95:713, 1995
61. Pasqualini R, Hemler ME: Constrasting roles for integrin beta 1 and beta 5 cytoplasmic domains in subcellular localization, cell proliferation and cell migration. J Cell Biol 125:447, 1994